GENFIT (GNFT) Stock Price, News & Analysis

Company Overview

Genfit is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory and metabolic diseases of the liver. The company’s lead program targets nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) through selective modulation of peroxisome proliferator-activated receptors (PPARs). In addition to its small-molecule pipeline, Genfit is advancing proprietary diagnostic tools designed to improve disease staging and patient stratification, underscoring its integrated approach to drug development and precision medicine.

The company’s most advanced asset, elafibranor, is a dual PPAR‐α/δ agonist that has undergone extensive clinical evaluation for NASH. Genfit’s research portfolio also includes pipelines for fibrosis and cholestatic liver diseases, as well as companion diagnostics such as the NIS4 panel, which measures gene expression markers to aid in noninvasive assessment of NASH severity. By combining therapeutic and diagnostic modalities, Genfit aims to address unmet needs in chronic liver disease and streamline clinical trial design.

Founded in 1999 as a spin-off from the University of Lille, Genfit has established a presence in Europe and North America, with corporate headquarters in Lille, France, and a research office in Cambridge, Massachusetts. Over the years, the company has fostered collaborations with academic institutions, patient advocacy groups and pharmaceutical partners to advance its clinical and diagnostic programs. Genfit’s global footprint enables it to conduct multicenter trials and access diverse patient populations.

Led by Chief Executive Officer Pascal Prigent, Genfit benefits from a management team with deep expertise in hepatology, regulatory affairs and commercial development. The company’s governance structure and strategic partnerships support its mission to bring first-in-class and best-in-class treatments to patients with serious liver conditions. As Genfit progresses through late-stage clinical milestones, it remains committed to leveraging scientific innovation and diagnostic precision to transform liver disease care.

Key Stats

• Today's Range: $3.82 to $3.85
• 50-Day Range: $3.61 to $4.51
• 52-Week Range: $2.55 to $6.42
• Volume: 2,773 shs
• Average Volume: 10,317 shs
• Market Capitalization: $193.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

GENFIT Stock Analysis - MarketRank™

GENFIT scored higher than 46% of companies evaluated by MarketBeat, and ranked 624th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

GENFIT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GENFIT has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GENFIT are expected to decrease in the coming year, from $0.95 to ($0.57) per share.

Price to Book Value per Share Ratio

GENFIT has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of GENFIT has been sold short.

Short Interest Ratio / Days to Cover

GENFIT has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GENFIT has recently decreased by 6.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GENFIT does not currently pay a dividend.

Dividend Growth

GENFIT does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of GENFIT has been sold short.

Short Interest Ratio / Days to Cover

GENFIT has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GENFIT has recently decreased by 6.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.74

News Sentiment

GENFIT has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for GENFIT this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GENFIT insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.20% of the stock of GENFIT is held by insiders.

Percentage Held by Institutions

Only 2.24% of the stock of GENFIT is held by institutions.

GNFT Stock Analysis - Frequently Asked Questions

How have GNFT shares performed this year?

GENFIT's stock was trading at $3.71 at the beginning of 2025. Since then, GNFT stock has increased by 4.3% and is now trading at $3.8690.

When did GENFIT IPO?

GENFIT (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

How do I buy shares of GENFIT?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GENFIT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GENFIT investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival (CCL).

Company Calendar

• Today: 7/16/2025
• Next Earnings (Estimated): 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNFT
• CIK: 1757064
• Web: www.genfit.com
• Phone: (332) 016-4000
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for GENFIT: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +238.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $67.00 million
• Price / Sales: 2.87
• Cash Flow: $0.07 per share
• Price / Cash Flow: 54.19
• Book Value: $1.50 per share
• Price / Book: 2.56

Miscellaneous

• Outstanding Shares: 50,003,000
• Free Float: 47,903,000
• Market Cap: $192.01 million
• Optionable: Not Optionable
• Beta: 1.08